Hal Hirte

10 papers receiving 338 citations

Peers

Hal Hirte
Comparison fields: 5 of 46
  • Reproductive Medicine 70
  • Obstetrics and Gynecology 41
  • Oncology 133
  • Cancer Research 46
  • Hematology 30
Replace C O'Flaherty with:
C O'Flaherty United States
Stephanie Morrissey United States
Josep M. del Campo Spain
YounJeong Choi United States
Karin Tyburski United States
M.A. Bensmaïne France
Jeffrey C. Goh Australia
Luisa Carrara Italy
K Sawaguchi Japan
U. Klaassen Germany
Hal Hirte relative to C O'Flaherty United States C O'Flaherty's profile →
Citations per field
00.5×3.3×
C O'Flaherty · 1×
Citations per year

Countries citing papers authored by Hal Hirte

Since Specialization
Citations

This map shows the geographic impact of Hal Hirte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hal Hirte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hal Hirte more than expected).

Fields of papers citing papers by Hal Hirte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hal Hirte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hal Hirte. The network helps show where Hal Hirte may publish in the future.

Co-authors

The 25 scholars most cited alongside Hal Hirte, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hal Hirte Line = papers co-authored together Hal Hirte links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1 2008103
2 200292
3 200550
4 200242
5 199123
6
An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + Platinum containing chemotherapy (CT)
200115
7 199311
8
Aflibercept (VEGF TRAP) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: results of a randomized, double-blind, placebo-controlled study
20097
9 20056
10 19912
11
A phase II trial of the histone deacetylase inhibitor Belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A trial of the PMH Phase II Consortium
20071
12 20031

About Hal Hirte

Hal Hirte is a scholar working on Reproductive Medicine, Oncology, Molecular Biology, Surgery and Pathology and Forensic Medicine, having authored 12 papers that have together received 353 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (8 papers), Angiogenesis and VEGF in Cancer (2 papers), Intraperitoneal and Appendiceal Malignancies (2 papers), Endometrial and Cervical Cancer Treatments (1 paper), Chemotherapy-induced organ toxicity mitigation (1 paper), Estrogen and related hormone effects (1 paper), Cancer Mechanisms and Therapy (1 paper) and Lung Cancer Research Studies (1 paper). The work is most often cited by research in Reproductive Medicine (70 citations), Obstetrics and Gynecology (41 citations), Oncology (133 citations), Cancer Research (46 citations) and Hematology (30 citations). Hal Hirte has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Sebastién J. Hotte, Laurie Elit, Martin Gleave, Elizabeth A. Eisenhauer, Kim N., Lillian L. Siu, Jean Powers, Dongsheng Tu, Wendy Walsh and Emma S. Tomlinson Guns. Their work appears in journals such as JNCI Journal of the National Cancer Institute, Current Opinion in Obstetrics & Gynecology, Clinical Cancer Research, International Journal of Gynecological Cancer and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact